FNY Investment Advisers LLC Increases Stock Position in Pfizer Inc. $PFE

FNY Investment Advisers LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 209.8% in the second quarter, HoldingsChannel reports. The firm owned 50,150 shares of the biopharmaceutical company’s stock after acquiring an additional 33,960 shares during the period. FNY Investment Advisers LLC’s holdings in Pfizer were worth $1,207,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Vanguard Group Inc. grew its stake in Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares during the period. KBC Group NV grew its position in shares of Pfizer by 8.3% in the fourth quarter. KBC Group NV now owns 9,193,713 shares of the biopharmaceutical company’s stock valued at $228,924,000 after purchasing an additional 706,426 shares during the period. North Dakota State Investment Board acquired a new position in Pfizer in the fourth quarter valued at $5,348,000. PFA Pension Forsikringsaktieselskab purchased a new position in Pfizer during the fourth quarter worth about $76,833,000. Finally, John G Ullman & Associates Inc. boosted its stake in Pfizer by 35.0% in the 4th quarter. John G Ullman & Associates Inc. now owns 206,065 shares of the biopharmaceutical company’s stock worth $5,131,000 after buying an additional 53,467 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 earnings beat and guidance increase: Pfizer reported adjusted earnings of $0.77 per share versus the $0.68 consensus estimate, while revenue of $15.03 billion exceeded expectations of $14.40 billion. Management raised the low end of its 2026 revenue outlook, supported by Eliquis and other non-COVID products. Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
• Positive Sentiment: Cost savings and pipeline support: Pfizer expanded its cost-reduction target, providing a potential lift to future margins and cash flow. Analysts also highlighted continued growth in newer products and a broader R&D pipeline as offsets to declining COVID revenue. PFE Q2 Deep Dive: New Products Offset COVID Decline, R&D Pipeline Expands
• Positive Sentiment: Clinical catalysts: Pfizer reported positive Phase 3 data for LITFULO in vitiligo and announced progress in a pediatric COVID booster study. It also completed a Phase 1 study of PF-07328948, adding incremental support to its longer-term pipeline narrative. Pfizer Reports Positive Phase 3 LITFULO Data in Vitiligo
• Neutral Sentiment: Analyst view remains mixed: Some coverage describes Pfizer as attractive for income investors because of its high dividend yield and potential undervaluation, while RBC Capital maintained a Hold rating. Investors remain focused on execution and the sustainability of the recovery. RBC Capital Remains a Hold on Pfizer
• Negative Sentiment: COVID and pipeline risks persist: COVID pill revenue reportedly fell 95%, and setbacks surrounding Pfizer’s obesity program, along with upcoming patent expirations, continue to raise concerns about long-term growth. These risks explain why the market’s response remains measured despite the earnings beat. Pfizer Covid Pill Revenue Plunges 95%

Pfizer Stock Performance

Pfizer stock opened at $26.18 on Friday. The company has a market cap of $149.24 billion, a price-to-earnings ratio of 34.45 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.94. The stock’s 50-day moving average is $25.01 and its 200-day moving average is $26.16.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 226.32%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on PFE. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Pfizer in a research note on Monday. BMO Capital Markets lowered their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Citigroup upped their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. Finally, Guggenheim lowered their price objective on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.50.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.